Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bioheng Publishes Positive Results for Universal CAR-T in Hematological Malignancies

publication date: Sep 26, 2022

Nanjing Bioheng Biotech published positive Phase I clinical study results of RD13-01, a universal anti-CD7 CAR-T therapy in the journal Cell Research. The first-in-human study showed the allogeneic CAR-T therapy was effective in patients with relapsed/refractory CD7-positive hematological malignancies. Of the 11 patients analyzed for efficacy, 9 (82%) had an objective response while 6 of 8 leukemia patients (75%) experienced minimal residual disease/complete remission. Bioheng focuses on novel cellular immunotherapies, most of which are allogeneic CAR-Ts aimed at hematologic and solid tumors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital